noscript

News and Announcements

Imugene (AXS: IMU) Commences Phase 1b/2 Gastric Cancer Study, Receives Approvals to Initiate Clinical Trial & Secures Further Intellectual Property

  • Published August 11, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Imugene Limited (ASX: IMU), an immunoncology company is pleased to release its Appendix 4C for the quarter ended 30th June, 2017.

KEY TAKEAWAYS:

  • Commenced the Phase 1b/2 gastric cancer study for HER-Vaxx
  • Received full and final country regulatory approvals to initiate clinical trial;
  • Commenced patient recruitment in all 8 clinical sites in Thailand, Taiwan and Hong Kong
  • Secured further intellectual property for HER-Vaxx
  • Completed further development of the next generation of mimotope targets and pipeline
  • Commenced in vivo testing of arginine modulator in animal models of cancer

Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

More Information

Request Information 

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now